Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HCFA Reimbursement For Epogen, Takeover Talk Help Amgen Grow In June

Executive Summary

A second increase in the Health Care Financing Administration reimbursement rates for Epogen has aided in increasing the valuation of Amgen in the financial community

You may also be interested in...



Amgen EPO Medicare Claims To Be Monitored Via Dose Levels – CMS Draft

Medicare claims for use of Amgen's Aranesp and Epogen in end-stage renal disease will be monitored through blood hematocrit or hemoglobin levels as well as dosage levels, a Centers for Medicare & Medicaid Services' draft policy says

Reimbursement Questions Jeopardize Hillrom/Bardy Merger

Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel